Mersana Therapeutics EBIT

Mersana Therapeutics (MRSN) currently reports a EBIT of $-60M as of September 2025. That compares with $-67M in the prior-year period — up 9.6% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Mersana Therapeutics's EBIT history and peer comparisons.

Mersana Therapeutics's EBIT increased from $-67M to $-60M — a 9.6% year-over-year increase (period ending September 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Mersana Therapeutics's EBIT of $-60M is lower than the Healthcare sector average of $23B. That is roughly 100.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Mersana Therapeutics reported $-60M in EBIT as of September 2025. That compares with $-67M in the prior-year period — up 9.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-60M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Mersana Therapeutics, and consider following MRSN for alerts when major investors trade the stock.